SCHEMBL25756409

SCHEMBL25756409

COC(=O)CCOCCOCCNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
CA12 O43570 4/20 0.42
CA2 P00918 4/20 0.42
CA1 P00915 3/20 0.42
CA9 Q16790 3/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
IDO1 P14902 1/20 0.40
CA14 Q9ULX7 1/20 0.40
BCHE P06276 1/20 0.39
CNR2 P34972 1/20 0.39
EPHX1 P07099 1/20 0.39
ADRB2 P07550 1/20 0.39
HTR1A P08908 1/20 0.39
SUCNR1 Q9BXA5 1/20 0.39
TSHR P16473 1/20 0.38
TLR2 O60603 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699508 1.00 TDP1 (0.46) TDP1MEN1KMT2AGAACA12
SCHEMBL22256341 1.00 TDP1 (0.46) TDP1MEN1KMT2AGAACA12
SCHEMBL21082300 1.00 TDP1 (0.46) TDP1MEN1KMT2AGAACA12
SCHEMBL21521446 0.98 TDP1 (0.47) TDP1MEN1KMT2AGAACA12
SCHEMBL19451348 0.92 TDP1 (0.47) TDP1MEN1KMT2AGAACA12
SCHEMBL18886420 0.92 TDP1 (0.47) TDP1MEN1KMT2AGAACA12
SCHEMBL24922459 0.92 TDP1 (0.40) TDP1MEN1KMT2AGAACA12
SCHEMBL26150015 0.91 TDP1 (0.47) TDP1MEN1KMT2AGAACA12
SCHEMBL14742521 0.90 TDP1 (0.49) TDP1MEN1KMT2AGAACA12
SCHEMBL28989738 0.89 TDP1 (0.46) TDP1MEN1KMT2AGAACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 TDP1 1380/4885MEN1 940/4885KMT2A 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.